AMPA receptor positive allosteric modulators: a patent review
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: AMPA receptors represent an interesting target to develop innovative therapeutic drugs such as positive allosteric modulators, a subclass of modulators known to potentiate the effect of glutamate through this kind of glutamatergic ionotropic receptors. The enhancement of AMPA signals is expected to be beneficial in the management of several neurological disorders, such as depression, schizophrenia, Parkinson's disease and learning-memory deficits linked to Alzheimer's disease. AMPA receptor positive allosteric modulators continue to be the object of intensive research as evidenced by the diversification in the range of chemotypes explored. AREAS COVERED: This article examines recent discoveries of new AMPA receptor modulators mainly described in the patent literature from 2008 to 2012. EXPERT OPINION: An important challenge is to discover an ideal drug candidate exhibiting appropriate in vivo activity after oral administration with an acceptable safety profile. The future remains promising because such compounds have proved to be able to stimulate the expression of the neurotrophic factor BDNF, a unique property opening interesting perspectives in new therapeutic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Receptor trafficking and synaptic plasticity
Collingridge, G. L., Isaac, J. T. R., & Wang, Y. T. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1556 · Cited by 1,046 · cited 1×
“Each subunit comprises a large extracellular domain incorporating the L-glutamate-binding site in the ligand-binding domain (LBD) [6], three membrane-spanning hydrophobic domains (M1, M3 and M4) and one intramembrane reentrant loop (M2) which constitutes part of the ion channel pore [7], and an intracellular domain co…”
BackgroundTargeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
A role for AMPA receptors in mood disorders
Alt, A., Nisenbaum, E. S., Bleakman, D., & Witkin, J. M. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.022 · Cited by 238 · cited 1×
“Enhancement of AMPA signals by AMPA receptor potentiators is, therefore, expected to be beneficial in the management of neurological disorders, such as depression [17], schizophrenia [18], Parkinson’s disease [10], Alzheimer’s disease [19], attention-deficit/hyperactivity disorder (ADHD) and mood disorders [20,21].”
BackgroundPalmer, C. L., Cotton, L., & Henley, J. M. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.7 · Cited by 211 · cited 1×
“AMPA receptors are tetrameric assemblies of subunits GluA1 -- 4 that arrange themselves in various stoichiometries, most of which being symmetric dimer-ofdimers of GluA2 and either GluA1, GluA3 or GluA4 [2-5].”
Background
Cited by
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Dendritic structural plasticity and neuropsychiatric disease
Forrest, M. P., Parnell, E., & Penzes, P. (2018) · Nature Reviews Neuroscience · doi:10.1038/nrn.2018.16 · Cited by 464
All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants
Freudenberg, F., Reif-Leonhard, C., Dawson, G. R., McKernan, R. M., & Reif, A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107918 · Cited by 23
Metadata
- Authors
- Pirotte, B., Francotte, P., Goffin, E., & de Tullio, P.
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa Healthcare
- Published
- 2013-02-13
- Volume
- 23
- Issue
- 5
- Pages
- 615-628
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W2002142985
- Cited by
- 52
- References
- 4
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.